Side effects
Nausea on GLP-1 medication
What the prescribing information for semaglutide, tirzepatide and oral semaglutide reports about nausea: how often it was recorded, in whom, and against placebo.
This page is general information, not medical advice. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality. A qualified clinician determines whether treatment is appropriate for you.
Generated from the family's dataset. No clinician has reviewed this page as a document.
What it is
Nausea is the feeling of being about to be sick, with or without actually being sick.
It is reported separately from vomiting in all three of the documents cited below, so a reader looking for one should not read the other's figure as covering it.
How often it was reported
The figures below come from the trials the branded products were approved on, and each one is shown against the placebo arm of the same trial. They describe the people in those studies — not anyone on this program, and not the compounded preparations this program dispenses.
The prescribing information for Wegovy lists nausea among the adverse reactions reported in the trials it was approved on. Measured in 44% of 2,116 adults taking 2.4 mg semaglutide weekly for 68 weeks, against 16% of 1,261 adults on placebo in the same trials. DailyMed, U.S. National Library of Medicine, 2026-06-30
The prescribing information for Zepbound lists nausea among the adverse reactions reported in the trials it was approved on. Measured in 28% of 941 adults taking 15 mg tirzepatide weekly for 72 weeks, against 8% of 958 adults on placebo in the same trials. DailyMed, U.S. National Library of Medicine, 2026-09-02
The prescribing information for Rybelsus lists nausea among the adverse reactions reported in the trials it was approved on. Measured in 20% of 356 adults with type 2 diabetes taking 14 mg oral semaglutide daily in placebo-controlled trials, against 6% of 362 adults with type 2 diabetes on placebo in the same trials. DailyMed, U.S. National Library of Medicine, 2026-08-19
What happens on this program
Before each refill your care team confirms your dose and checks in on how you are doing. If a reaction is making it hard to stay on the schedule you were given, that check-in is the place to say so — and you do not have to wait for it.
This page does not set a dose and does not change one. A prescribing clinician does both, and they are the only person on this program who can.
When to get help
Everything above reports what those documents themselves list. None of it is a judgement about what is happening to you: nobody who wrote this page has seen you, and reading a page is not a consultation.
If something is happening and you are not sure what it means, contact your provider or the pharmacy that dispensed to you. If it is severe, or you think it may be an emergency, call 911 or go to the nearest emergency room.
The prescribing information for Wegovy says nausea, vomiting and diarrhea can cause a loss of fluids, which may lead to kidney problems or make existing kidney problems worse, and directs a patient to tell a health care provider if they occur. DailyMed, U.S. National Library of Medicine, 2026-06-30
The prescribing information for Wegovy directs a patient to stop taking it and contact a health care provider promptly if severe abdominal pain that will not go away occurs, with or without vomiting, which it lists as a possible sign of inflammation of the pancreas. DailyMed, U.S. National Library of Medicine, 2026-06-30